Lexicon Pharmaceuticals | LXRX - Operating Expenses

Stock Price
1.65
Daily Change
0.02 0.92%
Monthly
33.74%
Yearly
347.38%
Q1 Forecast
1.43

Lexicon Pharmaceuticals reported $57M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Illumina USD 903M 69M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 18.97B 2.38B Dec/2025
Lexicon Pharmaceuticals USD 57M 10.54M Jun/2024
MacroGenics USD 67M 8M Sep/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Novartis USD 9.86B 115M Sep/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Thermo Fisher Scientific USD 9.91B 867M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025